Candel Therapeutics (CADL) Projected to Post Earnings on Thursday

Candel Therapeutics (NASDAQ:CADL) is projected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

Candel Therapeutics (NASDAQ:CADL) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.17). On average, analysts expect Candel Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Candel Therapeutics Stock Up 0.9 %

Shares of NASDAQ CADL opened at $8.90 on Thursday. The stock’s 50 day moving average price is $8.23 and its two-hundred day moving average price is $7.00. Candel Therapeutics has a 52-week low of $1.40 and a 52-week high of $14.60. The stock has a market capitalization of $289.04 million, a P/E ratio of -5.14 and a beta of -1.29.

Insider Transactions at Candel Therapeutics

In related news, insider Charles Schoch sold 5,000 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $8.83, for a total value of $44,150.00. Following the completion of the transaction, the insider now directly owns 38,038 shares of the company’s stock, valued at $335,875.54. This represents a 11.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CTO Seshu Tyagarajan sold 31,278 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $8.82, for a total value of $275,871.96. Following the completion of the transaction, the chief technology officer now directly owns 85,512 shares of the company’s stock, valued at $754,215.84. This trade represents a 26.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 77,807 shares of company stock worth $633,534. 41.60% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

CADL has been the topic of several research reports. Citigroup assumed coverage on Candel Therapeutics in a research note on Thursday, February 20th. They set a “buy” rating and a $25.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $19.00 price target on shares of Candel Therapeutics in a research report on Friday, March 14th. Canaccord Genuity Group increased their price target on Candel Therapeutics from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, February 26th. Finally, Bank of America assumed coverage on Candel Therapeutics in a research report on Friday, February 7th. They set a “buy” rating and a $15.00 price target on the stock.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.